洛伐他汀与Omega-3脂肪酸对老年混合型高脂血症患者的影响

The efficacy of lovastatin and omega-3 fatty acid in treatment of combined hyperlipidemia in old people

目的 评价洛伐他汀单用及与Omega 3脂肪酸联合治疗老年混合型高脂血症患者的疗效与安全性。方法 5 3例混合型高脂血症患者随机分为两组。洛伐他汀组 2 6例 ,给予洛伐他汀 2 0mg d ;洛伐他汀 +Omega 3组 2 7例 ,给予洛伐他汀 2 0mg d ,Omega 34.0 5g d ,治疗 8周 ,观察降脂疗效和不良反应。结果 洛伐他汀组总胆固醇 (TC)下降 2 4 .4 5 % ,达标率为 5 0 % ;低密度脂蛋白胆固醇 (LDL C)下降 36 .8% ,达标率为 6 5 .38% ;动脉硬化指数 ((TC HDL C) HDL C)下降 34.16 %。 (以上 3项均为 P <0 .0 0 1) ;甘油三酯 (TG)下降 6 .6 1% (P >0 .0 5 ) ,达标率为 4 2 .31% ;高密度脂蛋白 (HDL C)升高 4 .6 1%。洛伐他汀 +Omega 3组TC下降 2 4 .2 2 % ,达标率为 5 9.2 6 % ;LDL C下降2 1.82 % ,达标率为 70 .37% ;(TC HDL C) HDL C下降 34.90 %。 (以上 3项均为 P <0 .0 0 1) ;同时 ,TG下降 2 7.0 7% ,达标率为 6 2 .96 % ;HDL C升高 5 .38%。结论 洛伐他汀 +Omega 3组降低TG明显优于洛伐他汀组 ,降低TC、LDL C、(TC HDL C) HDL C ,二组差异无显著意义。但达标率洛伐他汀 +Omega 3脂肪酸组均高于洛伐他汀组。

Objective To evaluate the efficacy and safety of lovastatin and lovastatin+omega 3 fatty acid in treatment of combined hyperlipidemia in old people.Methods Fifty three cases with combined hyperlipidemia were randomly divided into 2 groups.One group consisted of 26 cases who were given lovastatin 20 mg/d for 8 weeks,and the other group consisted of 27 cases receiving lovastatin 20 mg/d and omega 3 fatty acid 4.05 g/d for 8 weeks.Results After 8 weeks, in lovastatin group, TC achieved 24.45% reduction and 50% under par;LDL C achieved 36.8% reduction and 65.38% under par;TC HDL C/HDL C achieved 34.16% reduction (P<0.001 for all these 3 indices);TG achieved 6.61% reduction and 42.31% under par(P> 0.05 ).The efficacy of decreasing TC,LDL C,TC HDL C/HDL C was similar in both groups,but lovastatin+omega 3 fatty acid was superior to lovastatin in decreasing TG. In lovastatin+omega 3 fatty acid group,TC achieved 24.22% reduction and 59.26% under par;LDL C achieved 21.82% reduction and 70.37% under par;TC HDL C/HDL C achieved 34.90% reduction(P<0.001 for all these 3 indices);TG achieved 27.07 % reduction and 62.96% under par.Conclusions Lovastatin+omega 3 fatty acid is significantly superior to lovastatin alone in reduction of TG and is similar in reduction of TC,LDL C,and TC HDL C/HDL C, but its rate of under par is higher than that of lovastatin.The HDL C elevation was not statistically significant in both groups (P>0.05).The lovastatin with omega 3 fatty acid used in treatment of combined hyperlipidemia is strongly suggested.